The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma. The Food and Drug Administration (FDA) has approved Aphexda ...

Neulasta (pegfilgrastim) is a brand-name drug that’s prescribed to treat radiation sickness and prevent certain complications of chemotherapy. Neulasta comes as an injectable solution. The dosage can ...

2016 and 2017 were difficult years for companies trying to win US Food and Drug Administration (FDA) approval for biosimilars of Amgen's blockbuster for treating side effects from chemotherapy. Last ...

The U.S. Food and Drug Administration has approved the first biosimilar to pegfilgrastim (Neulasta, Amgen), a granulocyte colony-stimulating factor used to reduce infection risk in patients with ...

- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...